Recommendation of direct antiviral therapy protocol and its safety for patients with hepatitis C / 中华临床感染病杂志

ABSTRACT

At present, drug therapies for hepatitis C patients are using a large variety of direct-acting antiviral agents (DAAs). In order to facilitate clinicians for selection of appropriate therapeutic agents, the author recommends Zepatier or Gilead third-generation (Epdusa) for treatment, and G/P cocktail (Maviret) therapy for patients with failure of other DAAs treatments. In this article, the author also discusses the safety and resistance rate of these small molecule drugs to provide reference for clinicians.